Peptide-based probes for targeted molecular imaging.

Targeted molecular imaging techniques have become indispensable tools in modern diagnostics because they provide accurate and specific diagnosis of disease information. Conventional nonspecific contrast agents suffer from low targeting efficiency; thus, the use of molecularly targeted imaging probes is needed depending on different imaging modalities. Although recent technologies have yielded various strategies for designing smart probes, utilization of peptide-based probes has been most successful. Phage display technology and combinatorial peptide chemistry have profoundly impacted the pool of available targeting peptides for the efficient and specific delivery of imaging labels. To date, selected peptides that target a variety of disease-related receptors and biomarkers are in place. These targeting peptides can be coupled with the appropriate imaging moieties or nanoplatforms on demand with the help of sophisticated bioconjugation or radiolabeling techniques. This review article examines the current trends in peptide-based imaging probes developed for in vivo applications. We discuss the advantage of and challenges in developing peptide-based probes and summarize current systems with respect to their unique design strategies and applications.

[1]  Anastasia Nikolopoulou,et al.  Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting , 2008, Journal of Nuclear Medicine.

[2]  Klemens Scheidhauer,et al.  Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Ettore Benedetti,et al.  Criteria for the Design and Biological Characterization of Radiolabeled Peptide-Based Pharmaceuticals , 2012, BioDrugs.

[4]  Sanjiv S Gambhir,et al.  Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. , 2006, Nano letters.

[5]  J. Reubi,et al.  NPY receptors in human cancer: A review of current knowledge , 2007, Peptides.

[6]  Matthias Friebe,et al.  Novel chemically modified analogues of neuropeptide Y for tumor targeting. , 2008, Bioconjugate chemistry.

[7]  J. Reubi,et al.  Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Weibo Cai,et al.  Are quantum dots ready for in vivo imaging in human subjects? , 2007, Nanoscale research letters.

[9]  Franz Buchegger,et al.  Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  Raoul Kopelman,et al.  Vascular Targeted Nanoparticles for Imaging and Treatment of Brain Tumors , 2006, Clinical Cancer Research.

[11]  Tomohiko Mori,et al.  Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. , 2006, Nuclear medicine and biology.

[12]  Jean-Pierre Vincent,et al.  Neurotensin receptors: Binding properties, transduction pathways, and structure , 1995, Cellular and Molecular Neurobiology.

[13]  Fan Wang,et al.  Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. , 2009, Journal of medicinal chemistry.

[14]  Abass Alavi,et al.  PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  Vasilis Ntziachristos,et al.  Inflammation in Atherosclerosis: Visualizing Matrix Metalloproteinase Action in Macrophages In Vivo , 2006, Circulation.

[16]  R. Moats,et al.  In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts , 2004, Cancer Research.

[17]  Fan Wang,et al.  68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin αvβ3 PET imaging , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Chenjie Xu,et al.  PET/MRI Dual-Modality Tumor Imaging Using Arginine-Glycine-Aspartic (RGD)–Conjugated Radiolabeled Iron Oxide Nanoparticles , 2008, Journal of Nuclear Medicine.

[19]  Georges von Degenfeld,et al.  Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. , 2007, Nature chemical biology.

[20]  D. Edwards,et al.  Cancer: Proteases — invasion and more , 1998, Nature.

[21]  Philippe Robert,et al.  Recent advances in iron oxide nanocrystal technology for medical imaging. , 2006, Advanced drug delivery reviews.

[22]  Subhani M Okarvi,et al.  Peptide‐based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases , 2004, Medicinal research reviews.

[23]  S. Nie,et al.  Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy , 2008 .

[24]  Tamitake Itoh,et al.  Semiconductor quantum dots and metal nanoparticles: syntheses, optical properties, and biological applications , 2008, Analytical and bioanalytical chemistry.

[25]  Richard P Baum,et al.  Imaging of neuroendocrine tumors. , 2006, Seminars in nuclear medicine.

[26]  David Piwnica-Worms,et al.  Single-cell imaging of retinal ganglion cell apoptosis with a cell-penetrating, activatable peptide probe in an in vivo glaucoma model , 2009, Proceedings of the National Academy of Sciences.

[27]  Igor L. Medintz,et al.  Quantum dot bioconjugates for imaging, labelling and sensing , 2005, Nature materials.

[28]  Weibo Cai,et al.  Imaging of integrins as biomarkers for tumor angiogenesis. , 2008, Current pharmaceutical design.

[29]  C Susini,et al.  Rationale for the use of somatostatin analogs as antitumor agents. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  J. Reubi,et al.  High Expression of Neuropeptide Y1 Receptors in Ewing Sarcoma Tumors , 2008, Clinical Cancer Research.

[31]  L. Brand,et al.  Resonance energy transfer: methods and applications. , 1994, Analytical biochemistry.

[32]  R. Weissleder,et al.  Fluorescence molecular tomography resolves protease activity in vivo , 2002, Nature Medicine.

[33]  Vasilis Ntziachristos,et al.  Shedding light onto live molecular targets , 2003, Nature Medicine.

[34]  Emanuel Christ,et al.  Glucagon-like peptide 1-receptor scans to localize occult insulinomas. , 2008, The New England journal of medicine.

[35]  G. Morelli,et al.  Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy. , 2004, Current pharmaceutical design.

[36]  H. Dai,et al.  In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. , 2020, Nature nanotechnology.

[37]  Eun Kyoung Ryu,et al.  18F-Labeled BBN-RGD Heterodimer for Prostate Cancer Imaging , 2008, Journal of Nuclear Medicine.

[38]  S. Gambhir,et al.  Noninvasive Raman spectroscopy in living mice for evaluation of tumor targeting with carbon nanotubes. , 2008, Nano letters.

[39]  Martin Gotthardt,et al.  Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  M A Horton,et al.  The alpha v beta 3 integrin "vitronectin receptor". , 1997, The international journal of biochemistry & cell biology.

[41]  J. Reubi,et al.  GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting , 2007, Journal of Nuclear Medicine.

[42]  Sol Kimel,et al.  Targeting small-cell lung cancer with novel fluorescent analogs of somatostatin. , 2005, Lung cancer.

[43]  Ick Chan Kwon,et al.  Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[44]  M. Walter,et al.  Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  Ralph Weissleder,et al.  In vivo imaging of molecularly targeted phage. , 2006, Neoplasia.

[46]  E. Krenning,et al.  Somatostatin receptor imaging. , 2002, Seminars in nuclear medicine.

[47]  Ralph Weissleder,et al.  In vivo molecular target assessment of matrix metalloproteinase inhibition , 2001, Nature Medicine.

[48]  J. Frangioni In vivo near-infrared fluorescence imaging. , 2003, Current opinion in chemical biology.

[49]  E Helene Sage,et al.  Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. , 2003, Cancer research.

[50]  M. Atkins,et al.  Interaction of an alpha-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases. , 1992, Cancer research.

[51]  Wole Soboyejo,et al.  LHRH-conjugated Magnetic Iron Oxide Nanoparticles for Detection of Breast Cancer Metastases , 2006, Breast Cancer Research and Treatment.

[52]  Yubin Miao,et al.  Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging. , 2007, Frontiers in bioscience : a journal and virtual library.

[53]  S. Schulz,et al.  New Pansomatostatin Ligands and Their Chelated Versions: Affinity Profile, Agonist Activity, Internalization, and Tumor Targeting , 2008, Clinical Cancer Research.

[54]  Thangavel Arunachalam,et al.  177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[55]  Ralph Weissleder,et al.  Nanoparticle imaging of integrins on tumor cells. , 2006, Neoplasia.

[56]  Weibo Cai,et al.  Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging , 2008, Nature Protocols.

[57]  David Piwnica-Worms,et al.  An improved cell-penetrating, caspase-activatable, near-infrared fluorescent peptide for apoptosis imaging. , 2009, Bioconjugate chemistry.

[58]  Alain Blanc,et al.  Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[59]  Kinneret Keren,et al.  Dynamic imaging of protease activity with fluorescently quenched activity-based probes , 2005, Nature chemical biology.

[60]  Ick Chan Kwon,et al.  Activatable imaging probes with amplified fluorescent signals. , 2008, Chemical communications.

[61]  Eduard Schreibmann,et al.  18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[62]  Byung-Heon Lee,et al.  Phage display selection of peptides that home to atherosclerotic plaques: IL-4 receptor as a candidate target in atherosclerosis , 2008, Journal of cellular and molecular medicine.

[63]  Sol Kimel,et al.  Diagnostic targeting of colon cancer using a novel fluorescent somatostatin conjugate in a mouse xenograft model , 2008, International journal of cancer.

[64]  Vasilis Ntziachristos,et al.  Looking and listening to light: the evolution of whole-body photonic imaging , 2005, Nature Biotechnology.

[65]  W. Semmler,et al.  Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands , 2001, Nature Biotechnology.

[66]  J. Reubi,et al.  Peptide-Based Probes for Cancer Imaging , 2008, Journal of Nuclear Medicine.

[67]  S. Gambhir,et al.  Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics , 2005, Science.

[68]  Martin A Walter,et al.  Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  C. Tung,et al.  Fluorescent peptide probes for in vivo diagnostic imaging , 2004, Biopolymers.

[70]  Ajay Kumar Gupta,et al.  Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. , 2005, Biomaterials.

[71]  J. Matthew Mauro,et al.  Long-term multiple color imaging of live cells using quantum dot bioconjugates , 2003, Nature Biotechnology.

[72]  S. Korsmeyer,et al.  Cell Death in Development , 1999, Cell.

[73]  Peter Hohenberger,et al.  68Ga-Labeled Bombesin Studies in Patients with Gastrointestinal Stromal Tumors: Comparison with 18F-FDG , 2007, Journal of Nuclear Medicine.

[74]  Horst Kessler,et al.  First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography , 2004, Clinical Cancer Research.

[75]  Ping Yu,et al.  In Vitro and In Vivo Evaluation of Alexa Fluor 680-Bombesin[7–14]NH2 Peptide Conjugate, a High-Affinity Fluorescent Probe with High Selectivity for the Gastrin-Releasing Peptide Receptor , 2007, Molecular imaging.

[76]  Chenjie Xu,et al.  Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. , 2008, Journal of the American Chemical Society.

[77]  J. Reubi Peptide receptors as molecular targets for cancer diagnosis and therapy. , 2003, Endocrine reviews.

[78]  Jean E Rivier,et al.  Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. , 2008, Journal of medicinal chemistry.

[79]  T J Hoffman,et al.  Evaluation of an (111)In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[80]  Harald Sontheimer,et al.  Chlorotoxin Inhibits Glioma Cell Invasion via Matrix Metalloproteinase-2* , 2003, The Journal of Biological Chemistry.

[81]  Christopher H Contag,et al.  Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. , 2008, Nature medicine.

[82]  M. Cybulsky,et al.  Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. , 1991, Science.

[83]  J. Reubi,et al.  Targeting CCK receptors in human cancers. , 2007, Current topics in medicinal chemistry.

[84]  A. Cuthbertson,et al.  NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. , 2006, Bioorganic & medicinal chemistry letters.

[85]  Wolfhard Semmler,et al.  Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. , 2007, Cancer research.

[86]  Weibo Cai,et al.  Near-Infrared Fluorescence Imaging of Tumor Integrin αvβ3 Expression with Cy7-Labeled RGD Multimers , 2006, Molecular Imaging and Biology.

[87]  Chad A Mirkin,et al.  Nanostructures in biodiagnostics. , 2005, Chemical reviews.

[88]  Sanjiv S. Gambhir,et al.  Dual-Function Probe for PET and Near-Infrared Fluorescence Imaging of Tumor Vasculature , 2007, Journal of Nuclear Medicine.

[89]  Judit Erchegyi,et al.  Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors , 2006, Proceedings of the National Academy of Sciences.

[90]  Young-Seung Kim,et al.  Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. , 2009, Bioconjugate chemistry.

[91]  Weibo Cai,et al.  Semiconductor quantum dots for in vivo imaging. , 2007, Journal of nanoscience and nanotechnology.

[92]  Valery A. Petrenko,et al.  Evolution of phage display: from bioactive peptides to bioselective nanomaterials , 2008 .

[93]  Anna M Wu,et al.  Antibodies for Molecular Imaging of Cancer , 2008, Cancer journal.

[94]  V. Ntziachristos Fluorescence molecular imaging. , 2006, Annual review of biomedical engineering.

[95]  J. Xie,et al.  Iron oxide nanoparticle platform for biomedical applications. , 2009, Current medicinal chemistry.

[96]  Kaijun Zhang,et al.  PET Imaging of VPAC1 Expression in Experimental and Spontaneous Prostate Cancer , 2007, Journal of Nuclear Medicine.

[97]  Ick Chan Kwon,et al.  Dark quenched matrix metalloproteinase fluorogenic probe for imaging osteoarthritis development in vivo. , 2008, Bioconjugate chemistry.

[98]  Pius August Schubiger,et al.  Molecular imaging with PET. , 2008, Chemical reviews.

[99]  Matthias Glaser,et al.  Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients , 2008, Journal of Nuclear Medicine.

[100]  Ick Chan Kwon,et al.  A new atherosclerotic lesion probe based on hydrophobically modified chitosan nanoparticles functionalized by the atherosclerotic plaque targeted peptides. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[101]  Klaas Nicolay,et al.  MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[102]  J C Reubi,et al.  Unexpected high incidence of cholecystokinin‐B/gastrin receptors in human medullary thyroid carcinomas , 1996, International journal of cancer.

[103]  Weibo Cai,et al.  Nanoplatforms for targeted molecular imaging in living subjects. , 2007, Small.

[104]  Martin Gotthardt,et al.  [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[105]  Sanjiv S Gambhir,et al.  Molecular imaging: the vision and opportunity for radiology in the future. , 2007, Radiology.

[106]  J. Habener,et al.  The glucagon-like peptides. , 1999, Endocrine reviews.

[107]  Joseph A Frank,et al.  Magnetic Tagging of Therapeutic Cells for MRI , 2009, Journal of Nuclear Medicine.

[108]  Rex Moats,et al.  18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. , 2004, Nuclear medicine and biology.

[109]  Patrick Pauwels,et al.  Gastrin-Releasing Peptide Receptor Imaging in Human Breast Carcinoma Versus Immunohistochemistry , 2008, Journal of Nuclear Medicine.

[110]  Young-Seung Kim,et al.  Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. , 2008, Journal of medicinal chemistry.

[111]  F Dumont,et al.  Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[112]  Shuming Nie,et al.  Bioconjugated quantum dots for in vivo molecular and cellular imaging. , 2008, Advanced drug delivery reviews.

[113]  C. Olbrich,et al.  Optical imaging in drug discovery and diagnostic applications. , 2005, Advanced drug delivery reviews.

[114]  A. Marcus,et al.  Imaging and tracking of tat peptide-conjugated quantum dots in living cells: new insights into nanoparticle uptake, intracellular transport, and vesicle shedding. , 2007, Journal of the American Chemical Society.

[115]  Jiqiu Chen,et al.  Near-Infrared Fluorescent Imaging of Matrix Metalloproteinase Activity After Myocardial Infarction , 2005, Circulation.

[116]  T. Hoffman,et al.  Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. , 2005, Nuclear medicine and biology.

[117]  Markus Schwaiger,et al.  [18F]Galacto-RGD Positron Emission Tomography for Imaging of αvβ3 Expression on the Neovasculature in Patients with Squamous Cell Carcinoma of the Head and Neck , 2007, Clinical Cancer Research.

[118]  R. M. Cook,et al.  Intramolecular dimers: a new design strategy for fluorescence-quenched probes. , 2003, Chemistry.

[119]  Michael J. Welch,et al.  Imaging of Melanoma Using 64Cu− and 86Y−DOTA−ReCCMSH(Arg11), a Cyclized Peptide Analogue of α-MSH , 2005 .

[120]  Sibylle Ziegler,et al.  Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .

[121]  S. Jurisson,et al.  In vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. , 1999, Nuclear medicine and biology.

[122]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[123]  Sanjiv S. Gambhir,et al.  How molecular imaging is speeding up antiangiogenic drug development , 2006, Molecular Cancer Therapeutics.

[124]  M. Montminy,et al.  Transcriptional regulation by cyclic AMP. , 1997, Annual review of biochemistry.

[125]  K. Brown,et al.  New approaches for cell-specific targeting: identification of cell-selective peptides from combinatorial libraries. , 2000, Current opinion in chemical biology.

[126]  Erkki Ruoslahti,et al.  A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[127]  Christian Bruns,et al.  Opportunities in somatostatin research: biological, chemical and therapeutic aspects , 2003, Nature Reviews Drug Discovery.

[128]  Kit S Lam,et al.  From combinatorial chemistry to cancer-targeting peptides. , 2007, Molecular pharmaceutics.

[129]  Veronique Maes,et al.  Novel 99mTc-labeled neurotensin analogues with optimized biodistribution properties. , 2006, Journal of medicinal chemistry.

[130]  E. D. de Vries,et al.  Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. , 2009, Critical reviews in oncology/hematology.

[131]  Sanjiv S. Gambhir,et al.  Near-Infrared Fluorescent RGD Peptides for Optical Imaging of Integrin αvβ3 Expression in Living Mice , 2005 .

[132]  J C Reubi,et al.  Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. , 2000, Cancer research.

[133]  D. Wong,et al.  Translating an Antagonist of Chemokine Receptor CXCR4: From Bench to Bedside , 2008, Clinical Cancer Research.

[134]  V. Hruby Designing peptide receptor agonists and antagonists , 2002, Nature Reviews Drug Discovery.

[135]  Donghoon Lee,et al.  In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. , 2008, Small.

[136]  Zhuang Liu,et al.  Carbon nanotubes as photoacoustic molecular imaging agents in living mice. , 2008, Nature nanotechnology.

[137]  S. Deutscher,et al.  Phage peptide display. , 2008, Handbook of experimental pharmacology.

[138]  Seulki Lee,et al.  Dual-Modality Probes for in Vivo Molecular Imaging , 2009, Molecular imaging.

[139]  J. Habener,et al.  Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. , 1996, Endocrinology.

[140]  Xianzhong Zhang,et al.  Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. , 2006, Nuclear medicine and biology.

[141]  A. Schally,et al.  Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[142]  Hariprasad Gali,et al.  Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[143]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.